Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

US Patent 11629196 · Granted Apr 18, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of assaying neoplastic and neoplasia-related cells and uses thereof2025
Methods of assigning a COVID pathological type based on a cytokine/chemokine pan2025
Methods of assigning a COVID pathological type based on a cytokine/chemokine pan2025
Methods of assigning a COVID pathological type based on a cytokine/chemokine pan2025
Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) inte2024
Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) inte2024
Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) inte2024
Method of treating hypercytokinemia by administering the CCR5/CCL5 (RANTES) inte2024
Methods of assaying neoplastic and neoplasia-related cells and uses thereof2023
Methods of treating a long-hauler subject for chronic COVID-19 by administering 2022
Methods of treating a long-hauler subject for chronic COVID-19 by administering 2022
Methods of treating a long-hauler subject for chronic COVID-19 by administering 2022